Recombinant Protein Expression Patents: Top Companies & Trends 2026
- Filings have plateaued, not grown. the peak year was 2018 at 24 records, and the 2022 midpoint of 20 shows the field flattening rather than accelerating.
- The top of the field is moderately concentrated. the five leading assignees together hold 29.7% of all 590 records in scope, rising to 45.4% across the top ten.
- Claim density sits heavily in two IPC classes. C12N covers 89.3% of records and C12P 51.4%, meaning most competitive collision happens in host-organism and fermentation claims, not downstream formulation.
What this landscape covers
This dataset tracks 590 patent records published between 2015 and mid-2026 that combine language around protein expression systems — E. coli, mammalian, yeast and insect cell platforms — with claim terms covering inclusion body refolding, codon optimization, post-translational modification and titer improvement. The scope is bounded by IPC classes C12N15, C12P21 and C12N1, which together anchor the field to genetic engineering of host organisms and the fermentation or enzymatic processes used to produce recombinant protein. Publication lags filing by roughly 18 months, so the most recent filing year is understated by construction.
Reading the field through patent families rather than raw document counts controls for the multi-jurisdiction and continuation filing that inflates activity for any single applicant. The receiving-office spread, concentrated across the United States, Europe, WIPO's PCT route, Israel, Canada and Australia, points to a field where applicants are still filing multi-jurisdiction protection rather than treating any one market as sufficient on its own.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 590 records: how filing activity has moved year over year, and which IPC subclasses carry the claim weight.
Filing activity has plateaued since 2018
Filings ran from 14 in 2017 to a peak of 24 in 2018, sat at 20 by the 2022 midpoint, and fell to 3 in the still-incomplete most recent year. Read as a whole, the curve shows a mature filing pattern rather than an accelerating one — later-year figures will revise upward as publication catches up, but the flat-to-declining midpoint trend is unlikely to reverse.
Claim density concentrates in host-organism and fermentation classes
C12N (microorganisms and genetic engineering) appears on 89.3% of the 590 records in scope, and C12P (fermentation and enzymatic synthesis) on 51.4% — together they mark where most competitive claim collision happens. C07K (peptides and proteins) at 44.2% and the smaller therapeutic-application classes (A61K, A61P) sit further downstream, suggesting that host-engineering and production-process claims are more contested than formulation or indication claims.
Shares are the percentage of the 590 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Recombinant Protein Expression Systems with Eureka
This page is one run against one query. Ask Eureka your own question about recombinant protein expression systems and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited records in this space
Dnmt3b Gene-Deficient CHO Cell Line for Recombinant Protein Expression
The invention relates to genetic engineering, and more particularly to a Dnmt3b gene-deficient CHO cell line, a preparation method and an application thereof and a recombinant protein expression system using the same. The invention adopts a CRISPR/Cas9 gene editing technique to knock out the Dnmt3b gene from the CHO cells to produce the Dnmt3b gene-deficient CHO cell line, which can significantly improve the expression level and stability of the target gene in CHO cells, overcoming defects such as low expression level and stability in current CHO expression systems.Filed by Xinxiang Medical University, published 2021-01-07. Demonstrated against recombinant adalimumab expression as a working example.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20090239259A1 | Mammalian expression vectors and uses thereof | 206 |
| 2 | US20110081708A1 | Method of Sequence Optimization for Improved Recombinant Protein Expression using a Particle Swarm Optimizati… | 154 |
| 3 | US5935824A | Protein expression system | 95 |
| 4 | US8187836B2 | Mammalian expression vectors and uses thereof | 87 |
| 5 | US20080096252A1 | Production and purification of il-29 | 87 |
| 6 | US6521419B1 | Expression vectors containing hot spot for increased recombinant protein expression in transfected cells | 76 |
| 7 | US5672485A | Immortalized cell lines for virus growth | 76 |
| 8 | US5879924A | Immortalized cell lines for virus growth | 74 |
| 9 | US6800457B2 | Expression vectors containing hot spot for increased recombinant protein expression in transfected cells | 57 |
| 10 | US20030138908A1 | Expression vectors containing hot spot for increased recombinant protein expression in transfected cells | 45 |
Citation counts reflect influence within this searched corpus and skew toward older filings; treat them as a signal of prior-art density, not of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data means for R&D and IP strategy
Three read-throughs from the filing trend, the citation table and the IPC composition.
The field is filing at a steady, not rising, pace
With the 2022 midpoint at 20 records against a 2018 peak of 24, new entrants are not accelerating claim volume. That makes this a field where a well-drafted claim can still hold ground rather than being buried under a wave of new filings.
Moderate concentration, long tail beneath it
The leader holds 49 records against a fifth-place figure of 25 and a tenth-place figure of 13 — a real gap at the very top, but the drop from top-5 to top-10 share (29.7% to 45.4%) shows plenty of active mid-tier filers rather than a two-company duopoly.
Host-engineering claims dominate the corpus
Almost nine in ten records touch C12N (microorganisms and genetic engineering), while downstream therapeutic-activity classes like A61P sit at 9.2%. Strategy built around host-cell modification is entering the most crowded part of the map; work anchored in measuring/testing (C12Q, 5.4%) or animal-system claims (A01K, 4.7%) faces far less prior art.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to recombinant protein expression systems, with the prior art for and against each one.
| Assignee | Co-assignee | Shared families |
|---|---|---|
| Biocon Ltd | Center of Molecular Immunology | 19 |
| ZymoGenetics Inc | Bristol Myers Squibb Co | 6 |
| Merck & Co | ZHUANG JUN | 2 |
| Merck & Co | JIANG BO | 2 |
| Regeneron Pharmaceuticals Inc | FANDL JAMES | 1 |
| Regeneron Pharmaceuticals Inc | DESHPANDE DIPALI | 1 |
| Regeneron Pharmaceuticals Inc | CHEN GANG | 1 |
| Regeneron Pharmaceuticals Inc | BURAKOV DARYA | 1 |
Only 10 co-assignee pairs appear in the dataset, and the strongest pair co-files far more often than the rest combined — most applicants in this field prosecute alone rather than through joint ventures.
The assignee landscape
The ranking covers 100 companies across all 590 records in scope — not a top-50 or top-100 cut, but the full ranked field the dataset returns.
A clear leader, not a runaway one
The top assignee holds 49 records against 25 at fifth place and 13 at tenth — enough of a gap to matter for freedom-to-operate work, but not enough to treat the space as owned by a single player.
Recent-year filing has gone quiet across former leaders
Several of the most historically active assignees show zero filings in the latest year of the dataset. Combined with the flat overall trend, this points to a field where incumbents are consolidating existing portfolios rather than actively expanding claim scope.
Joint filing is the exception
Co-assignee activity is limited to 10 pairs, with one pair filing jointly far more often than any other combination. Most organisations in this space are building their portfolios independently rather than through cross-licensing or joint-venture structures.
| Assignee | Recent year | YoY |
|---|---|---|
| Regeneron Pharmaceuticals Inc | 0 | — |
| ZymoGenetics Inc | 0 | — |
| CMC ICOS Biologics Inc | 0 | — |
| Alternative Gene Expression | 0 | — |
| Biocon Ltd | 0 | — |
| Regents of the University of Minnesota | 0 | — |
| Bristol Myers Squibb Co | 0 | — |
| Center of Molecular Immunology | 0 | — |
Where to take this analysis
The landscape points to specific follow-up work depending on whether the goal is freedom-to-operate, licensing, or new filing strategy.
Map claims against the leading assignees' active families
With 45.4% of records held by the top ten assignees, a freedom-to-operate review should start with their most recent active families before assuming open ground.
Explore assignee portfolios in EurekaTest draft claims against the under-claimed IPC branches
Classes like C12Q and A01K carry a fraction of the record share that C12N does, which is a starting point for scoping new claims rather than a guarantee of allowability.
Run a claim-scope check in EurekaTrack filing momentum before committing R&D spend
Several historically dominant filers show zero activity in the latest year — worth confirming whether that reflects portfolio maturity or a shift in filing strategy before assuming the space is static.
Set up momentum alerts in EurekaCommon questions on recombinant protein expression patents
The leading assignee in this dataset holds 49 of the 590 records in scope, with a noticeable drop to 25 records at fifth place and 13 at tenth. That gap suggests one organisation has built a materially larger position than the rest of the field, but the top ten together still only account for 45.4% of all records, leaving substantial ground held by a long tail of smaller filers. Anyone assessing competitive exposure should look at both the leader's portfolio and the mid-tier filers, since the field is concentrated but not monopolised.
Filing activity peaked at 24 records in 2018 and has not returned to that level since, with the 2022 midpoint sitting at 20 records and a marked decline shown in the most recent, still-incomplete year. This pattern reads as flat-to-declining rather than growing. Because publication typically lags filing by around 18 months, the very last year of data will revise upward, but the multi-year trend through the midpoint does not indicate an expanding field.
C12N, covering microorganisms and genetic engineering, appears on 89.3% of the 590 records in scope, making it by far the most heavily claimed class. C12P (fermentation and enzymatic synthesis) follows at 51.4%, and C07K (peptides and proteins) at 44.2%. Downstream classes tied to therapeutic use, such as A61K and A61P, appear on a much smaller share of records, indicating that most patent activity centres on host-organism engineering and production processes rather than final therapeutic formulation.
The IPC composition shows several classes with comparatively low record share against the corpus, including C12Q (measuring and testing, 5.4%) and A01K (animal husbandry, 4.7%), which point to less-claimed sub-areas such as enzymatic titer assays and transgenic animal expression hosts. Low record share is not proof of patentability, but it does indicate lighter prior-art density than the crowded C12N and C12P classes. A prudent approach is to draft claims that sit at the intersection of a crowded core class and one of these lighter-claimed branches, rather than filing squarely inside C12N alone.
Moderately concentrated: the top five assignees together hold 29.7% of the 590 records in scope, and the top ten hold 45.4%. That leaves more than half the field spread across the remaining ranked assignees, which is not the profile of a field dominated by two or three players. Recent-year momentum data also shows several previously active leaders posting zero filings in the latest year, suggesting the current concentration reflects historical filing rather than an actively widening lead.
Research Recombinant Protein Expression Systems in depth with Eureka
Go past this page: query the whole recombinant protein expression systems corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.